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Abstract
Benznidazole, drug of choice for Chagas disease (CD), has been associated with a high incidence of adverse reactions that 
can become serious, necessitating discontinuation of the drug. We describe the case of a Bolivian patient living in Spain for 
9 years, who, following treatment with benznidazole for CD in indeterminate chronic phase, presented with fever, skin lesions, 
digestive symptoms, general malaise, and laboratory abnormalities. After the discontinuation of benznidazole and, the intake of 
antihistamines and systemic corticosteroids, the patient presented a complete resolution of the symptoms. Optimization of dose 
strategies and development of more effective, and better-tolerated drugs is advisable.
Keywords: Adverse drug reaction. Benznidazole. Chagas disease.
INTRODUCTION
Benznidazole is considered the first option to treat Chagas 
disease (CD) in Spain and is used in both the acute and chronic 
phases1. The administration of the drug is associated with an 
elevated incidence of adverse reactions, mostly controlled with 
symptomatic treatment. However, some adverse reactions may 
become severe, necessitating discontinuation of the drug2. 
Chagas disease is a parasitic disease with a high socioeconomic 
impact. It is endemic in Latin America, where approximately 6-8 
million people are infected with Trypanosoma cruzi, and more 
than 100 million people live at risk of infection3. The incidence 
of new infections is 41,200 per annum and the mortality rate is 
12,500 deaths per annum1. In recent years, CD has expanded 
worldwide due to migration; Spain has the highest prevalence 
of CD in Europe4.
Chagas disease usually spreads through the sting of an 
infected hematophagous vector (e.g., bedbugs or insects from 
the subfamily Triatominae). Transmission is also possible 
through maternal-fetal exchange, blood transfusion, and organ 
transplantation. These forms of transmission are more typical 
in non-endemic areas. 
Asymptomatic individuals, with low levels of the parasite in 
the blood and other tissues, can still be a source of transmission4, 
making the diagnosis and treatment of these patients an 
important public health challenge5.
We describe the case of a patient who, after beginning 
treatment with benznidazole for CD, presented with an adverse 
systemic reaction, with fever, cutaneous and digestive symptoms, 
as well as general malaise and laboratory abnormalities, all of 
which led to discontinuation of the drug. 
CASE REPORT
A 49 year-old woman, originally from Bolivian (Santa Cruz), 
living in Spain for 9 years, serologically diagnosed in September 
2014 with CD, and in the indeterminate chronic phase with 
no digestive or cardiac involvement, began therapy with 
benznidazole in April 2015. Her daily dose, which corresponded 
to her weight of 60kg, was 300mg (5mg/kg/day). The patient 
noticed an erythematous, painful, and itchy plaque with a high 
edge in the left armpit 4 days after beginning treatment; this 
gradually increased in size. On the eighth day of treatment, 
she reported abdominal pain, nausea and vomiting, malaise, 
and dysthermia. On physical examination, she presented with 
low-grade fever (37.6ºC), erythematous papules with intense 
itchiness on the abdomen and lower back, a 20-cm left axillary 
indurated plaque covering all of the axilla and part of the left 
lateral side of the chest (Figure 1), and a palpable, mobile, 
and painful left axillary adenopathy (4cm in diameter). Blood 
analysis showed increased C-reactive protein (70.6mg/L), 
elevated aspartate aminotransferase (AST) (92IU/L) and alanine 
aminotransferase (ALT) (39IU/L), mild neutrophilia, and 
eosinophilia. When her blood analysis was compared with tests 
previously performed by her general practitioner, eosinophilia 
was noted to have been present since 2011 (Figure 2). The 
timing of the clinical manifestations and the laboratory findings 
suggested the episode was drug-induced. Administration of 
benznidazole was suspended and the patient started receiving 
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FIGURE 1 - Erythematous lesions in abdomen and indurated plaque in the left 
axilla and lateral side of the chest. Eight days after the beginning of treatment 
with benznidazole.
2013-01-28 2014-02-25 2015-02-03 2015-03-16* 2015-03-03
Leukocytes (10³/µL) 9.98 7.89 8.29 9.8 10.6
Neutrophils (10³/µL) 3.4 3.51 3.03 7.76 5.65
Eosinophils (10³/µL) 0.84 0.75 0.8 0.85 0.7
CPR (mg/L) 5.5 7.2 9.9 70.6
AST (U/L) 18 21 17 92 15







FIGURE 2 - Laboratory parameters. CRP: C-reactive protein; AST: aspartate aminotransferase; ALT: alanine aminotransferase. * Blood analysis before the 
discontinuation of benznidazol.
treatment with hydroxyzine (25mg at night-time), an extra dose 
of cetirizine (10mg after 12 hours if the pruritus was persistent), 
and prednisolone (30mg for 3 days, followed by a reduction of 
10mg every 3 days over 9 days of treatment). 
The gastrointestinal and systemic symptoms disappeared, 
with clear improvement of the skin lesions, 3 days after 
discontinuation of benznidazole. After a further 4 days, only a 
patch of residual post-inflammatory hyperpigmentation remained 
in the axilla and the adenopathy had disappeared. The patient was 
afebrile and laboratory parameters were within the normal range 
(Figure 2). After 6 months of the reaction, the patient started 
treatment with nifurtimox, with increasing doses for 10 days until 
getting the full dose (10 mg/kg/day). Seven days after starting this 
medication, she complained of abdominal pain and fever. Blood 
analysis showed leukocytosis (13.24 x 103/µl) and increase of 
eosinophilia (1.06 x 103/µl).  In agreement with the patient the 
drug was suspended. In further revisions the patient is clinically 
stable, and except for the persistent eosinophilia and elevated total 
IgE serum levels, the laboratory parameters are normal. Stool 
examinations were repeatedly negative for parasites. 
DISCUSSION
We report the case of an adverse reaction to benznidazole 
that presented with fever, malaise, skin lesions, gastrointestinal 
symptoms, and impaired hepatic function in a Bolivian woman 
in the indeterminate chronic phase of CD. 
The indeterminate chronic phase of CD is defined as the pre-
clinical period when the patient shows no signs or symptoms 
of the disease, despite positive serology. Up to 70% of patients 
with CD in the chronic phase remain in the indeterminate 
phase but, over time, up to 30% will develop cardiac 
abnormalities, between 10% and 20% digestive tract alterations 
(typically megaesophagus or megacolon), and 5% neurological 
disorders. 
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The pharmacological treatment of CD has barely changed in 
the past 30 years. The drugs currently available are nifurtimox 
and benznidazole. Both drugs have variable efficacy (depending 
on the dose, duration of the disease, age, and origin of the 
patient).
Treatment in the chronic phase is controversial due to the 
high frequency of adverse effects2. However, benznidazole has 
been shown to result in negative CD polymerase chain reaction 
assays, to reduce long-term seropositivity, slow the progression 
of cardiomyopathy, and possibly decrease mother-to-child and 
blood donor-related transmission2,3.
Benznidazole, a synthetic drug of the nitroimidazole group, 
is the only antitrypanosomal drug currently marketed in Spain. 
Although in children most adverse reactions due to benznidazole 
are mild6, in adults the frequency of these adverse reactions 
necessitates discontinuation of the drug in 10-20% of cases7. 
The dose for adults of 5.0-7.5mg/kg/day for 30-60 days, divided 
into 2 or 3 doses per day, has been demonstrated to be effective 
and without toxic effects8. The primary site for benznidazole 
metabolism is the liver, via the cytochrome P450 system and, to 
a lesser extent, oxidoreductase, xanthine oxidase, and aldehyde 
oxidase. The mechanism of action is based on the enzymatic 
reduction of the nitro group, which leads to the formation of 
chemically active species, considered free radicals, which interact 
with deoxyribonucleic acid (DNA), proteins, lipids, and other 
cellular components8. These mechanisms are responsible for both the 
therapeutic action against Trypanosoma cruzi and the adverse effects.
The most common adverse reactions involve the skin and 
occur in up to 30% of patients; they include a variety of itchy 
lesions (maculopapular rash, urticaria, morbilliform exanthema, 
or eczema) that usually appear 10-15 days after starting 
benznidazole5,6. Administration of antihistamines ameliorates 
these symptoms. The development of exfoliative dermatitis 
with fever and lymphadenopathy necessitates the immediate 
discontinuation of benznidazole. 
Even though benznidazole alone may cause painful lymph 
nodes, in the case we report, the rapid appearance of the initial 
lesion in the axilla accompanied by local adenopathy raised 
the possibility of other conditions, such as the skin infections 
cellulitis or erysipelas. However, in these conditions, the fever is 
usually more severe and malaise more pronounced. Furthermore, 
the satellite lesions and the laboratory abnormalities were not 
suggestive of an acute infectious process, and the lesion resolved 
after discontinuation the drug without the addition of antibiotics. 
Due to the location of the lesion, our patient’s diagnosis 
could have been confused with hidradenitis; however, this 
infection of the apocrine glands has a chronic course, including 
formation of abscesses. Candidiasis of the skinfolds, another 
possible differential diagnosis, is usually accompanied by a 
whitish secretion and responds only to specific treatment.
Differential diagnoses may also include severe skin 
reactions with systemic involvement. Drug reactions involving 
eosinophilia and systemic symptoms have been reported, but the 
eosinophilia with which our patient presented had been stable 
in recent years, and was possibly justified by the parasitosis 
itself. The cutaneous involvement did not meet the criteria for 
Stevens-Johnson syndrome or toxic epidermal necrolysis. The 
patient did not report any trauma or insect bite in the area.
Gastrointestinal symptoms occur in 5.6% of patients9, 
usually presenting as nausea, vomiting, epigastric pain, 
and decreased appetite or anorexia. Often these symptoms 
resolve with symptomatic treatment and are rarely a cause for 
discontinuation of the drug.
Benznidazole may induce elevation in the levels of 
transaminases and cholesterol. Our patient showed an increase 
in AST and ALT levels, which normalized 7 days after 
discontinuation of the drug (Figure 2).
Even if not in this patient, other adverse effect can 
occur. Peripheral neuropathy with paraesthesia often occurs 
at the end of treatment and is associated with toxicity2,8. 
Bone marrow damage caused by benznidazole is rare and 
necessitates immediate withdrawal of the drug. In some cases, 
thrombocytopenic purpura and/or leukopenia may appear2.
The case described illustrates the adverse effects, which 
include a variety of signs and symptoms, caused by the drug. 
It highlights the importance of differential diagnosis of the 
presenting symptoms, and the need to optimize dose strategies 
with the available drugs, evaluating their risk-benefit balance 
in the chronic phase of CD. The development of new, more 
effective, and better-tolerated drugs is advisable. 
Conflict of interest
The authors declare that there is no conflict of interest. 
REFERENCES
1. Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González 
MC, Zamora J, López-Velez R. Use of benznidazole to treat 
chronic Chagas' disease: a systematic review with a meta-analysis. 
J Antimicrob Chemother. 2009;64(61):1139-47. 
2. Viotti R,  Vigliano C,  Lococo B,  Alvarez MG,  Petti M,  Bertocchi G, et 
al. Side effects of benznidazole as treatment in chronic Chagas disease: 
fears and realities. Expert Rev Anti Infect Ther. 2009;7(2):157-63.
3. World Heath Organization (WHO). Chagas disease (American 
trypanosomiasis) Fact sheet, Nº 340. WHO; 2015. Available at: 
http://www.who.int/mediacentre/factsheets/fs340/es/ 
4. Schmunis GA. Epidemiology of Chagas disease in non-endemic 
countries: the role of international migration. Mem Inst Oswaldo 
Cruz. 2007;102(Suppl I):75-85. 
5. Pinazo MJ,  Muñoz J,  Posada E,  López-Chejade P,  Gállego M,  Ayala 
E, et al.  Gascon J. Tolerance of benznidazole in treatment of Chagas’ 
disease in adults. Antimicrob Agents Chemother. 2010;54(11):4896-99.
6. Miller DA, Salvador Hernandez S, De Armas LR, Eells SJ, Traina 
MM, Miller LG, et al. Tolerance of benznidazole in a United States 
Chagas Disease Clinic. Clin Infect Dis. 2015;60(8):1237-40.
7. Urbina JA. Recent clinical trials for the etiological treatment of 
chronic chagas disease: advances, challenges and perspectives. 
J Eukaryot Microbiol. 2015;62(1):149-56. 
8. Soy D, Aldasoro E, Guerrero L, Posada E, Serret N, Mejía T, et al. 
Population pharmacokinetics of benznidazole in adult patients with 
Chagas disease. Antimicrob Agents Chemother. 2015;59(6):3342-49. 
9. Antinori S, Grande R, Bianco R, Traversi L, Cogliati C, Torzillo 
D, et al. High frequency of adverse reactions and discontinuation 
with benznidazole treatment for chronic Chagas disease in Milan, 
Italy. Clin Infect Dis. 2015;60(12):1873-5.
